76884
Anthranilamide
suitable for matrix substance for MALDI-MS, ≥99.0% (HPLC)
Sinónimos:
2-AB, 2-Aminobenzamide, Anthranilic acid amide
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula lineal:
2-(H2N)C6H4CONH2
Número CAS:
Peso molecular:
136.15
UNSPSC Code:
23151817
NACRES:
NA.21
PubChem Substance ID:
EC Number:
201-851-2
Beilstein/REAXYS Number:
508509
MDL number:
Assay:
≥99% (NT), ≥99.0% (HPLC)
Form:
crystals
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleQuality Level
assay
≥99% (NT), ≥99.0% (HPLC)
form
crystals
technique(s)
MALDI-MS: suitable
mp
111-113 °C (lit.)
cation traces
Ba: ≤5 mg/kg, Ca: ≤5 mg/kg, Cd: ≤5 mg/kg, Co: ≤5 mg/kg, Cr: ≤5 mg/kg, Cu: ≤5 mg/kg, Fe: ≤30 mg/kg, K: ≤50 mg/kg, Mg: ≤5 mg/kg, Mn: ≤5 mg/kg, Na: ≤150 mg/kg, Ni: ≤5 mg/kg, Pb: ≤5 mg/kg, Zn: ≤5 mg/kg
suitability
suitable for matrix substance for MALDI-MS
SMILES string
NC(=O)c1ccccc1N
InChI
1S/C7H8N2O/c8-6-4-2-1-3-5(6)7(9)10/h1-4H,8H2,(H2,9,10)
InChI key
PXBFMLJZNCDSMP-UHFFFAOYSA-N
Application
Used for non-selective, efficient fluorescent labeling of glycans. Slightly less sensitive than anthranilic acid (2-AA) for glycan labeling.
Analysis Note
metal trace analysis (ICP) corresponds to requirements
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 1
flash_point_f
>365.0 °F
flash_point_c
> 185 °C
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Yan Cai et al.
The Analyst, 138(21), 6270-6276 (2013-09-07)
Analysis of oligosaccharides by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is often limited by their low ionization efficiency and inadequate fragmentation information. Derivatizations of oligosaccharides to enhance their ionization in MS are widely used, but most of these
Antonio da Silva et al.
Leukemia & lymphoma, 55(7), 1609-1617 (2013-09-13)
Biosimilar development involves a target-directed iterative process to ensure a similar product to the originator. Here we report the preclinical development of the proposed biosimilar rituximab (GP2013). Post-translational modifications and bioactivities of GP2013 versus originator rituximab were engineered and monitored
Nicholas T Ventham et al.
PloS one, 10(4), e0123028-e0123028 (2015-04-02)
Serum N-glycans have been identified as putative biomarkers for numerous diseases. The impact of different serum sample tubes and processing methods on N-glycan analysis has received relatively little attention. This study aimed to determine the effect of different sample tubes